DC Chemicals · Product datasheet

Tegatrabetan — Datasheet

CAT. NO. DC20756

Product page and current package options

ParameterValue
Chemical Name9,10-Anthracenedione, 2,7-bis[[(3R,5S)-3,5-dimethyl-1-piperidinyl]sulfonyl]-, 9,10-dioxime, rel-
CAS No.1227637-23-1
SynonymsBC-2059;BC2059;Tegavivint
FormulaC28H36N4O6S2
M.Wt588.74
SMILESO=S(C1=CC2=C(C=C1)/C(C3=CC=C(S(=O)(N4C[C@H](C)C[C@H](C)C4)=O)C=C3/C2=N\O)=N\O)(N5C[C@H](C)C[C@H](C)C5)=O
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

Tegatrabetan (BC2059) is a β-Catenin antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1)[1].

In Vitro

Tegatrabetan (BC2059; 20-100 nM; 48 hours) inhibits cell proliferation in suspension culture over 120 hours and induces apoptosis of cultured human acute myeloid leukemia (AML) HL-60, OCI-AML3 and MV4-11 cells dose-dependently[1]. Tegatrabetan (20 and 50 nM; 24 hours) induces a modest but significant accumulation of cells in the G0/G1 phase, with a concomitant decline in the G2/M phase of the cell cycle[1]. Tegatrabetan (100 nM, 24 hours) depletes the levels of β-catenin and its target genes, including c-MYC and survivin without affecting the levels of the TBL1 in OCI-AML3, HL-60 and MV4-11 cells[1]. Cell Proliferation Assay[1] Cell Line: HL-60, OCI-AML3 and MV4-11 cells Concentration: 20, 50, and 100 nM Incubation Time: 48 hours Result: Dose-dependently inhibited cell proliferation. Cell Cycle Analysis[1] Cell Line: OCI-AML3 cells Concentration: 20 and 50 nM Incubation Time: 24 hours Result: Dose-dependently induced cell cycle growth arrest. Western Blot Analysis[1] Cell Line: OCI-AML3, HL-60 and MV4-11 cells Concentration: 100 nM Incubation Time: 24 hours Result: Treatment depleted β-Catenin expression levels.

In Vivo

Tegatrabetan (BC2059; 1.0 or 5.0 mg/kg/day; intravenously) significantly improves the median survival of the mice from approximately 17.5 to 39 days. Treatment with Tegatrabetan (10 mg/kg/day; intravenously) alone further improves the median survival to 51.5 days[1]. Animal Model: NOD/SCID mice bearing OCI-AML3 xenografts[1] Dosage: 1 mg/kg; 5 mg/kg; 10 mg/kg Administration: Intravenously; 1 mg/kg daily 4 days per week or 5 mg/kg or 10 mg/kg of BC2059 twice per week (Tuesday and Thursday) for 3 weeks. Result: Treatment significantly improved survival of NOD/SCID mice bearing OCI-AML3 xenografts.

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation